In this episode, we discuss the final analysis of the KEYNOTE-826 subgroup study led by Dr. Yong-Man Kim, evaluating pembrolizumab plus chemotherapy with or without bevacizumab in East Asian patients with persistent, recurrent, or metastatic cervical cancer. The study demonstrated substantial improvements in progression-free and overall survival compared to placebo, with median progression-free survival reaching 18.0 months versus 10.4 months in the overall population, and 29.3 versus 10.9 months in patients with PD-L1 expression. Safety was consistent with the known profile of pembrolizumab. These findings support its use as a standard of care in this population.
--------
5:50
JGO Weekly Summary (March 25, 2025)
In this episode of the Journal of Gynecologic Oncology podcast, we review a recent meta-analysis by Tianyu Zhang and colleagues titled "Role of Adjuvant Chemotherapy in Stage IC Ovarian Granulosa Cell Tumors." The study analyzed data from 12 retrospective studies involving 695 patients to evaluate whether postoperative adjuvant chemotherapy offers any benefit over observation alone. The findings revealed no significant differences in recurrence, mortality, or five-year survival outcomes between the two groups, including across subtypes and chemotherapy regimens. These results suggest limited therapeutic value of adjuvant chemotherapy in stage IC granulosa cell tumors and underscore the need for individualized treatment approaches.Role of adjuvant chemotherapy in stage IC ovarian granulosa cell tumors: a systematic review and meta-analysis
--------
5:33
JGO Weekly Summary (March 18, 2025)
In this episode of the Journal of Gynecologic Oncology podcast, we discuss a study by Baldwin and colleagues titled Evaluation of the Role of Liver Metastasectomy in the Treatment of Stage IV Endometrial Cancer. Using data from the National Cancer Database, the researchers analyzed outcomes in 999 patients with metastatic endometrial cancer confined to the liver. The study found that patients who underwent both chemotherapy and surgical removal of liver metastases had improved survival compared to those who received chemotherapy alone, with a median survival of 20.1 months versus 14.6 months. While the findings suggest a potential benefit of metastasectomy, adjusted analysis did not reach statistical significance, highlighting the need for further prospective studies. Tune in to learn more about the evolving role of surgery in metastatic endometrial cancer treatment.Evaluation of the role of liver metastasectomy in the treatment of stage IV endometrial cancer
--------
4:39
JGO Weekly Summary (March 11, 2025)
This episode explores a recent study on the increased risk of cardiovascular disease among adolescent and young adult survivors of cervical cancer. Using data from the Korean National Health Insurance Service, researchers found that these survivors face a 47% higher risk of cardiovascular disease compared to non-cancer controls, with those receiving chemoradiotherapy at particularly high risk for heart failure, ischemic heart disease, and venous thromboembolism. The findings highlight the need for long-term cardiovascular monitoring and preventive care in this population. Tune in to learn more about the implications for survivorship care.Increased cardiovascular disease risk among adolescent and young adult survivors of cervical cancer
--------
5:09
JGO Weekly Summary (March 4, 2025)
This episode discusses a multi-institutional study evaluating the impact of bevacizumab in frontline chemotherapy for advanced ovarian clear cell carcinoma. Researchers analyzed data from 178 patients treated between 2008 and 2018 and found that adding bevacizumab significantly improved progression-free and overall survival. Patients who received bevacizumab had a median progression-free survival of 29.7 months compared to 10.5 months in those who did not. Median overall survival was 51.4 months versus 27.4 months. These findings suggest that bevacizumab may be an effective addition to first-line treatment for this rare and chemoresistant ovarian cancer. Tune in to learn more about the study and its clinical implications.Bevacizumab in frontline chemotherapy improved the survival outcome for advanced ovarian clear cell carcinoma: A multicenter retrospective analysis
The Journal of Gynecologic Oncology (JGO) is an official publication of the Asian Society of Gynecologic Oncology (ASGO), the Korean Society of Gynecologic Oncology (KSGO), the Japan Society of Gynecologic Oncology (JSGO), and the Society of Gynecologic Oncology of Canada (GOC).
Brasil